ANGO 250117 2.50P (ANGO250117P2500) Stock Options, News & Quotes

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

ANGO250117P2500

Watchlist

0.00
0.000.00%

15min DelayTrading Jan 22 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

AngioDynamics Highlights Strategic Growth at Healthcare Conference
TipRanksJan 16 16:28 ET
AngioDynamics Announces 35.5% Clot Reduction With AlphaVac F1885 System in Trial, Meeting Primary Endpoints In Pulmonary Embolism Treatment Published In The Journal Of The Society For Cardiovascular Angiography & Interventions Titled "Novel Mechanical...
BenzingaJan 13 08:37 ET
AngioDynamics Announces Publication of APEX-AV Trial Results in JSCAI
BusinesswireJan 13 08:00 ET
Oppenheimer Maintains AngioDynamics(ANGO.US) With Buy Rating, Raises Target Price to $16
Moomoo NewsJan 10 10:31 ET · Ratings
AngioDynamics Analyst Ratings
BenzingaJan 10 08:30 ET · Ratings
H.C. Wainwright Maintains AngioDynamics(ANGO.US) With Buy Rating, Raises Target Price to $15
Moomoo NewsJan 10 06:31 ET · Ratings

Comments

Trytosaveabit

Dec 9, 2024 12:42

$AngioDynamics (ANGO.US)$ Not to shabby! Lets try to push for a NHOD? Hehehe

Trytosaveabit

Dec 9, 2024 05:04

News

$AngioDynamics (ANGO.US)$ The FDA Has Granted 510(k) Clearance For AngioDynamics' Nanoknife System For Prostate Tissue Ablation
Benzinga· 1 min ago

Jaguar8

Dec 9, 2024 05:01

NEWS

$AngioDynamics (ANGO.US)$
AngioDynamics Receives FDA Clearance for The NanoKnife® System for Prostate Tissue Ablation
AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for the NanoKnife System for prostate tissue ablation.
Th...

Trytosaveabit

Oct 23, 2024 07:15

Update

$AngioDynamics (ANGO.US)$ Benzinga· 1 min ago
AngioDynamics, University College London Hospital Launch International Multi-Center Study On Long Term Effects Of Treatment With NanoKnife System

Jaguar8

Sep 19, 2024 15:48

NEWS

$AngioDynamics (ANGO.US)$
AngioDynamics Initiates RECOVER-AV Clinical Trial Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism and Long-Term Functional Outcomes
AngioDynamics, Inc. (NASDAQ: ANGO) has launched the RECOVER-AV clinical trial to evaluate the AlphaVac F18⁸⁵ System for treating acute, intermediate-risk pulmonary embolism (PE) in the European market.
This multi-center, multi-national study follows the successful APEX-AV trial in the US, which showed significant impr...